[The use of fenazid in patients with pulmonary tuberculosis with poor isoniazid tolerance].
The paper shows the experience gained in the use of the new Russian antituberculous drug fenazid in patients with different forms of active pulmonary tuberculosis and with neuro- and angiotoxic reactions to isoniazid. The study group comprised 25 patients aged 23 to 70 years who received fenazid as tablets in a daily dose of 0.5 g for 2 months at the first stage of the basic course of chemotherapy. The control group including 24 patients of the same age was given the routine antituberculous chemotherapy regimen, including isoniazid. The use of fenazid permits adequate therapy in patients with poor isoniazid tolerance, which may recommend fenazid to individuals at high risk for adverse reactions as their prevention.
Borisova
M I
MI
Stakhanov
V A
VA
Sharkova
T I
TI
Ivashchenko
N A
NA
D000328:Adult; D000368:Aged; D000995:Antitubercular Agents / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007502:Iron Chelating Agents / Q000737:chemistry*; D007538:Isoniazid / Q000008:administration & dosage / Q000009:adverse effects* / Q000031:analogs & derivatives*; D008297:Male; D008875:Middle Aged; D009942:Organometallic Compounds / Q000008:administration & dosage / Q000009:adverse effects*; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*
D000995:Antitubercular Agents; D007502:Iron Chelating Agents; D009942:Organometallic Compounds; D007538:Isoniazid